Iranian Journal of Pathology

Bioinformatics Analysis of Peroxisomal Biogenesis Factor Proteins in Breast Malignancy for Introducing Potential Prognostic Biomarkers

Document Type : Original Research

Authors

Nima Mahdei Nasirmahalleh 1
Mina Hemmati 2
Negin Parsamanesh 3, 4

1 Student Research Committee, Department of Medical Biochemistry, School of Medicine, Zanjan, Iran

2 Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

3 Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran

4 Department of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

https://doi.org/10.30699/ijp.2025.2030953.3311
Abstract
Background & Objective: Breast cancer (BC) is the most common type of malignant neoplasm and is the primary cause of mortality among women aged 45 to 55 years. Studies indicate that cancer displays irregular metabolic patterns in contrast to normal tissue. Furthermore, there is compelling evidence supporting the significant role of peroxisomes in the intricate metabolic processes of cancer. Peroxisomal biogenesis factors (PEXs), which are peroxisomal proteins, control activities such as the degradation and biogenesis of peroxisomes. Hence, the correlation between peroxisomal biogenesis factor expression and BC was explored, to introduce key proteins and potential biomarkers by analyzing.
Methods: This study utilized UALCAN, GenExMiner v4.8, Metascape, STRING, TIMER, the Kaplan-Meier plotter, The Human Protein Atlas, MirTarBase, and cBioportal.
Results: The transcriptional levels of PEX6/7/10/11B/13/16 in BC tissues were significantly elevated, whereas the transcriptional levels of PEX2/3/5/11A/12/19 were significantly reduced. High expression levels of PEX 2/3/10/12/11G /26/13/16/14 were significantly related to shorter relapse-free survival, and higher mRNA expression of PEX 11B/11G/11A/12/19 was significantly associated with longer overall survival of BC patients. We identified has-miR-4318 and has-7106-3p as more correlated miRNAs with the PEX family.
Conclusion: Our results may provide novel insights for the selection of therapeutic targets and prognostic biomarkers for BC. 

Keywords

Peroxine
Breast Tumor
Prognostic Marker

Subjects

  1.  

    1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029-30. [DOI:10.1002/cncr.33587] [PMID]
    2. Safaee A, Zeighami B, Tabatabaee H, Moghimi Dehkordi B. Quality of life and related factors in breast cancer patients under chemotherapy. Iranian Journal of Epidemiology. 2008;3(3):61-6. [DOI:10.4103/0019-509X.44066] [PMID]
    3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49. [DOI:10.3322/caac.20006] [PMID]
    4. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 2021;4(4):e214708. [DOI:10.1001/jamanetworkopen.2021.4708] [PMID] [PMCID]
    5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI:10.3322/caac.21660] [PMID]
    6. Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, et al. Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev. 2014;15(8):3353-8. [DOI:10.7314/APJCP.2014.15.8.3353] [PMID]
    7. Ghorbani-Abdi-Saedabad A, Hanafi-Bojd MY, Parsamanesh N, Tayarani-Najaran Z, Mollaei H, Hoshyar R. Anticancer and apoptotic activities of parthenolide in combination with epirubicin in mda-mb-468 breast cancer cells. Mol Biol Rep. 2020;47(8):5807-15. [DOI:10.1007/s11033-020-05649-3] [PMID]
    8. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72. [DOI:10.5858/134.7.e48] [PMID]
    9. Cai M, Sun X, Wang W, Lian Z, Wu P, Han S, et al. Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells. Cancer Lett. 2018;421:82-93. [DOI:10.1016/j.canlet.2018.02.021] [PMID]
    10. Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, et al. Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci U S A. 2013;110(37):14912-7. [DOI:10.1073/pnas.1310894110] [PMID] [PMCID]
    11. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. The American journal of surgical pathology. 2002;26(7):926-31. [DOI:10.1097/00000478-200207000-00012] [PMID]
    12. Mohamadian M, Parsamanesh N, Chiti H, Sathyapalan T, Sahebkar A. Protective effects of curcumin on ischemia/reperfusion injury. Phytother Res. 2022; 36(12):4299-324. [DOI:10.1002/ptr.7620] [PMID]
    13. Waterham HR, Ferdinandusse S, Wanders RJ. Human disorders of peroxisome metabolism and biogenesis. Biochim Biophys Acta. 2016;1863(5):922-33. [DOI:10.1016/j.bbamcr.2015.11.015] [PMID]
    14. Islinger M, Voelkl A, Fahimi HD, Schrader M. The peroxisome: an update on mysteries 2.0. Histochem Cell Biol. 2018;150(5):443-71. [DOI:10.1007/s00418-018-1722-5] [PMID]
    15. Fransen M, Nordgren M, Wang B, Apanasets O. Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. Biochim Biophys Acta. 2012;1822(9):1363-73. [DOI:10.1016/j.bbadis.2011.12.001] [PMID]
    16. Kim JA. Peroxisome Metabolism in Cancer. Cells. 2020;9(7):1692. [DOI:10.3390/cells9071692] [PMID] [PMCID]
    17. Dahabieh MS, Di Pietro E, Jangal M, Goncalves C, Witcher M, Braverman NE, et al. Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism. Biochim Biophys Acta Rev Cancer. 2018;1870(1):103-21. [DOI:10.1016/j.bbcan.2018.07.004] [PMID]
    18. Benedetti E, Galzio R, Laurenti G, D'Angelo B, Melchiorre E, Cifone M, et al. Lipid metabolism impairment in human gliomas: expression of peroxisomal proteins in human gliomas at different grades of malignancy. International Journal of Immunopathology and Pharmacology. 2010;23(1): 235-46. [DOI:10.1177/039463201002300121] [PMID]
    19. Jo DS, Park NY, Cho DH. Peroxisome quality control and dysregulated lipid metabolism in neurodegenerative diseases. Exp Mol Med. 2020; 52(9):1486-95. [DOI:10.1038/s12276-020-00503-9] [PMID] [PMCID]
    20. Cho DH, Kim YS, Jo DS, Choe SK, Jo EK. Pexophagy: Molecular Mechanisms and Implications for Health and Diseases. Mol Cells. 2018;41(1):55-64. [DOI: 10.14348/molcells.2018.2245] [PMID] [PMCID]
    21. Braverman NE, Raymond GV, Rizzo WB, Moser AB, Wilkinson ME, Stone EM, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab. 2016;117(3): 313-21. [DOI:10.1016/j.ymgme.2015.12.009] [PMID] [PMCID]
    22. Amiri-Dashatan N, Koushki M, Jalilian A, Ahmadi NA, Rezaei-Tavirani M. Integrated Bioinformatics Analysis of mRNAs and miRNAs Identified Potential Biomarkers of Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2020;21(6):1841-8.[PMCID] [DOI:10.31557/APJCP.2020.21.6.1841] [PMID]
    23. Amiri Dash Atan N, Koushki M, Rezaei Tavirani M, Ahmadi NA. Protein-Protein Interaction Network Analysis of Salivary Proteomic Data in Oral Cancer Cases. Asian Pac J Cancer Prev. 2018 Jun 25;19(6): 1639-1645. [DOI: 10.22034/APJCP.2018.19.6.1639] [PMCID] [PMID]
    24. Scott HS, Blanch L, Guo XH, Freeman C, Orsborn A, Baker E, et al. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet. 1995;11(4):465-7. [DOI:10.1038/ng1295-465] [PMID]
    25. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-W102. [DOI:10.1093/nar/gkx247] [PMID] [PMCID]
    26. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649-58. [DOI:10.1016/j.neo.2017.05.002] [PMID] [PMCID]
    27. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47(D1):D607-D13. [DOI:10.1093/nar/gky1131] [PMID] [PMCID]
    28. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e10. [DOI:10.1158/0008-5472.CAN-17-0307] [PMID] [PMCID]
    29. Zhao D. Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN deficient cancer. Cancer Res. 2019;79(13_Supplement):95-. [DOI:10.1158/1538-7445.AM2019-95]
    30. Fujiki Y, Okumoto K, Mukai S, Honsho M, Tamura S. Peroxisome biogenesis in mammalian cells. Front Physiol. 2014;5:307. [DOI:10.3389/fphys.2014.00307] [PMID] [PMCID]
    31. Lee MY, Sumpter Jr R, Zou Z, Sirasanagandla S, Wei Y, Mishra P, et al. Peroxisomal protein PEX 13 functions in selective autophagy. EMBO reports. 2017;18(1):48-60. [DOI:10.15252/embr.201642443] [PMID] [PMCID]
    32. Lauer C, Volkl A, Riedl S, Fahimi HD, Beier K. Impairment of peroxisomal biogenesis in human colon carcinoma. Carcinogenesis. 1999;20(6):985-9. [DOI:10.1093/carcin/20.6.985] [PMID]
    33. Keller JM, Cablé S, El Bouhtoury F, Heusser S, Scotto C, Armbruster L, et al. Peroxisome through cell differentiation and neoplasia. Biol Cell. 1993;77(1):77-88. [DOI:10.1016/S0248-4900(05)80177-7] [PMID]
    34. Litwin JA, Beier K, Volkl A, Hofmann WJ, Fahimi HD. Immunocytochemical investigation of catalase and peroxisomal lipid beta-oxidation enzymes in human hepatocellular tumors and liver cirrhosis. Virchows Arch. 1999;435(5):486-95. [DOI:10.1007/s004280050432] [PMID]
    35. Farre JC, Mahalingam SS, Proietto M, Subramani S. Peroxisome biogenesis, membrane contact sites, and quality control. EMBO Rep. 2019;20(1):e46864. [DOI:10.15252/embr.201846864] [PMID] [PMCID]
    36. Dahabieh MS, Ha Z, Di Pietro E, Nichol JN, Bolt AM, Goncalves C, et al. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. Cell Death Differ. 2017;24(11):1912-24. [DOI:10.1038/cdd.2017.115] [PMID] [PMCID]
Iranian Journal of Pathology
Volume 20, Issue 2
Spring 2025
Pages 181-197

  • Receive Date 02 June 2024
  • Revise Date 19 September 2024
  • Accept Date 03 November 2024

Home

Guide for Authors

Submit Manuscript

Contact Us